等待開盤 03-26 09:30:00 美东时间
-17.270
-35.24%
HC Wainwright & Co. analyst Ananda Ghosh maintains Maze Therapeutics (NASDAQ:MAZE) with a Buy and raises the price target from $60 to $110.
03-25 23:07
Companies Reporting Before The Bell • Chewy (NYSE:CHWY) is expected to report q...
03-25 19:11
Maze Therapeutics (NASDAQ:MAZE) reported quarterly losses of $(0.65) per share which beat the analyst consensus estimate of $(0.71) by 8.45 percent.
03-25 19:05
今日重点评级关注:花旗:维持Candel Therapeutics"买入"评级,目标价从22美元升至26美元;Chardan Capital:维持CervoMed"买入"评级,目标价从15美元升至21美元
03-19 14:31
Wall Street analysts have changed their outlook on top names, with new coverage and price targets. See the latest analyst ratings and opinions.
03-18 20:00
今日重点评级关注:HC Wainwright & Co.:维持Altimmune"买入"评级,目标价从12美元升至25美元;BTIG:维持Jade Biosciences"买入"评级,目标价从28美元升至39美元
03-17 11:45
Wedbush analyst Laura Chico maintains Maze Therapeutics (NASDAQ:MAZE) with a Outperform and raises the price target from $43 to $58.
03-16 20:26
今日重点评级关注:Oppenheimer:维持Corbus制药控股"跑赢大市"评级,目标价从53美元升至57美元;Canaccord Genuity:维持WAVE Life Sciences"买入"评级,目标价从43美元升至52美元
03-11 12:40
Analysts change outlook on top names, including initiations, upgrades, and downgrades. MSTR has a $175 price target and CROX has a Neutral rating.
03-10 20:50
今日重点评级关注:Evercore ISI集团:维持Caribou Biosciences"跑赢大市"评级,目标价从11美元升至13美元;富国银行:上调uniQure评级至"超配",目标价从15美元升至60美元
03-10 15:05